Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

The study objective is to provide current estimates of utilization/spending trends for molecular diagnostic and genetic testing for commercially insured, Medicare and Medicaid populations.

PRNewswireNew York [US]/ London [UK]/ Munich [Germany]/ New Delhi [India], February 11: Datar Cancer Genetics (DCG), a global ...

This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic ...

Global in vitro diagnostics (IVD) market will reach $148,393.3 million by 2031, growing by 6.3% annually over 2021-2031. The global in vitro diagnostics (IVD) market encompasses a wide range of ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company, announced on Monday, that it has regained compliance with Nasdaq's continued listing requirements. The company ...

Continued innovation and investment in molecular diagnostics will ensure broader access and better preparedness for HMPV, its variants and other respiratory illnesses.